Assisted reproduction and breast cancer

Minerva Ginecologica

Volumn 59, Issue 4, 2007, Pages 403-414

  Sonmezer, M ^a   Atabekoglu, C ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Breast neoplasms; Chemotherapy; Fertility; Ovarian failure, premature; Ovulation induction

Indexed keywords

ANASTROZOLE; BLEOMYCIN; BUSULFAN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CLOMIFENE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN; FLUOROURACIL; FOLLITROPIN; GONADORELIN; GONADOTROPIN; LETROZOLE; MELPHALAN; METHOTREXATE; PACLITAXEL; PROCARBAZINE; SPHINGOSINE 1 PHOSPHATE; TAMOXIFEN; TAXANE DERIVATIVE; VINCRISTINE;

AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; COMBINATION CHEMOTHERAPY; CRYOPRESERVATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ESTROGEN BLOOD LEVEL; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; HUMAN; MENSTRUAL CYCLE; MONOTHERAPY; OOCYTE; OVARY INSUFFICIENCY; OVULATION INDUCTION; QUALITY OF LIFE; REPRODUCTION; RISK ASSESSMENT; TREATMENT OUTCOME;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CRYOPRESERVATION; EMBRYO TRANSFER; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; INFERTILITY, FEMALE; NITRILES; OVARIAN FAILURE, PREMATURE; OVULATION INDUCTION; PREGNANCY; QUALITY OF LIFE; REPRODUCTIVE TECHNIQUES, ASSISTED; TAMOXIFEN; TRIAZOLES;

EID: 36348957235     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
2. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56;168-83.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
4. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003;53:342-55.
5. Oktay KH, Yih M. Preliminary experience with orthotopic and heterotopic transplantation of ovarian cortical strips. Semin Reprod Med 2002;20:63-74.
6. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31.
7. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315:559-63.
8. Figueiredo JC, Ennis M, Knight JA, McLaughlin JR, Hood N, O'Malley F et al. Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res Treat 2006 Nov 18; [Epub ahead of print]
9. Thewes B, Meiser B, Taylor A Phillips KA, Pendlebury S Capp A et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005;23:5155-65.
10. Colleoni M, Rotmensz N, Robertson C, Orianda L, Viale G, Renne G et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002;13:273-9.
11. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347-53.
12. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology 2004;13:295-308.
13. Partridge AH, Gelber S, Peppercorn J, Sapmson E, Knudsen K, Laufer M et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004;22:4174-83.
14. Degner LF, Kristjanson LJ, Bowman D Sloan JA, Carriere KC, O'Neil J et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997;277:1485-92.
15. Key T, Appleby P, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
16. Pike MC, Spicer DV, Dahmoush L, Pres MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
17. Pittaway DE, Wentz AC. Evaluation of the exponential rise of serum estradiol concentrations in human menopausal gonadotropin-induced cycles. Fertil Steril 1983;40:763-7.
18. Pena JE, Chang PL, Chan LK, Zeitoun K, Thornton MH, Sauer MV. Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles. Hum Reprod 2002;17:83-7.
19. Bolton P. Bilateral breast cancer associated with clomiphene. Lancet 1977;2:1176.
20. Laing RW, Glaser MG, Barrett GS. A case of breast carcinoma in association with in vitro fertilization. J R Soc Med 1989;82:503.
21. Arbour L, Narod S, Glendon G, Pollak M, Seymour R, Miner L et al. In-vitro fertilisation and family history of breast cancer. Lancet 1994;344:610-1.
22. Brzezinski A, Peretz T, Mor-Yosef S, Schenker JG. Ovarian stimulation and breast cancer: is there a link? Gynecol Oncol 1994;52:292-5.
23. Jourdain O, Avril A, Mauriac L, Quenel N, Bussieres E, Roux D et al. Breast cancer and in vitro fertilization. About 32 cases. Eur J Obstet Gynecol Reprod Biol 1996;67:47-52.
24. Unkila-Kallio L, Leminen A, Tiitnen A Lehtovirta P, Wahlström T, Ylikorkala O. Malignant tumors of the ovary or the breast in association with infertility: a report of thirteen cases. Acta Obstet Gynecol Scand 1997;76:177-81.
25. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987;125:780-90
26. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346:995-1000.
27. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354:1586-90.
28. Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S. Fertility treatment and risk of breast cancer. Hum Reprod 1996;11:300-3.
29. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038-42.
30. Ricci E, Parazzini F, Negri E, Marsico S, La Vecchia C. Fertility drugs and the risk of breast cancer. Hum Reprod 1999;14:1653-5.
31. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209-13.
32. Lerner-Geva L, Geva E, Lessing J, Chetrit A, Modan B, Amit A. The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer 2003;13:23-7.
33. Gauthier E, Paoletti X, Clavel-Chapelon F, and the E3N group. Breast cancer risk associated with being treated for infertility: results from the French E3N. Hum Reprod 2004;19:2216-21.
34. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77:324-7.
35. Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Althuis MD, Mabie JE et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004;19:2005-13.
36. Sonmezer M, Akar ME, Oktay K. Strong family history in women who were diagnosed with breast cancer after in vitro fertilization. Fertil Steril 2005;84 Suppl 1:S233-4.
37. Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973;289:1159-62.
38. Ratts VS, Flaws JA, Kolp R, Sorenson CM, Tilly JL. Ablation of bcl-2 gene expression decreases the numbers of oocytes and primordial follicles established in the post-natal female mouse gonad. Endocrinology 1995;136:3665-8.
39. Tilly JL, Kolesnick RN. Realizing the promise of apoptosis-based therapies: separating the living from the clinically undead. Cell Death Differ 2003;10:493-5.
40. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004;10:251-66.
41. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
42. Glück S. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 2005;10;780-91.
43. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006;11:422-34.
44. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29.
45. Goodwin PJ, Ennis M, Pritchard KI Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-70.
46. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-8.
47. Stone ER, Slack RS, Vovielli A, Ellis M, Baidas S, Gelmann E et al. Rate of chemotherapy related amenorrhea associated with adjuvant Adriamycin and Cytoxan and Adriamycin and Cytoxan followed by Taxol in early stage breast cancer. Breast Cancer Res Treat 2000;64:61a.
48. Reh AE, Oktem O, Lostritto K, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective analysis by menstrual history and ovarian reserve markers. Fertil Steril 2006;86 Suppl 1:97s-98s
49. Nabholtz J, Pienkowski T, Mackey J Pawlicki M, Guastalla JP, Vogel C et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002;21:36a.
50. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999;14:1903-7.
51. Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 1999;5:275-82.
52. Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in longterm bone marrow transplant survivors receiving busulfancyclophosphamide (120 mg/kg). Bone Marrow Transplant 2000;26:1089-95.
53. Veeck LL, Bodine R, Clarke RN, Berrios R, Libraro J, Moschini RM et al. High pregnancy rates can be achieved after freezing and thawing human blastocysts. Fertil Steril 2004;82:1418.
54. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347-53.
55. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006;91:3885-90.
56. Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2007 Mar 13 [Epub ahead of print]
57. Klopper A, Hall M. New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J 1971;1:152-4.
58. Pfister CU, Martoni A, Zamagni C, Lelli G, De Braud F, Souppart C et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 2001;22:191-7.
59. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
60. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005;23:3858-9.
61. Fatemi HM, Kolibianakis E, Tournaye H, Tournaye H, Donoso P, Papanikolaou E et al. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online 2003;7:543-6.
62. Chen C. Pregnancy after human oocyte cryopreservation. Lancet 1986;1:884-6.
63. Oktay, K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006;86:70.
64. Gosden RG. Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr 2005;(34):60-3.
65. Porcu E, Venturoli S. Progress with oocyte cryopreservation. Curr Opin Obstet Gynecol 2006;18:273-9.
66. Chian RC. In-vitro maturation of immature oocytes for infertile women with PCOS. Reprod Biomed Online 2004;8:547-52.
67. Tucker MJ, Wright G, Morton PC, Massey JB. Birth after cryopreservation of immature oocytes with subsequent in vitro maturation. Fertil Steril 1998;70:578-9.
68. Wu J, Zhang L, Wang X. In vitro maturation, fertilization and embryo development after ultrarapid freezing of immature human oocytes. Reproduction 2001;121:389-93.
69. Li Y, Feng HL, Cao YJ, Zheng GJ, Yang Y, Mullen S et al. Confocal microscopic analysis of the spindle and chromosome configurations of human oocytes matured in vitro. Fertil Steril 2006,85:827.
70. Soderstrom-Anttila V, Salokorpi T, Pihlaja M, Serenius-Sirve S, Suikkari AM. Obstetric and perinatal outcome and preliminary results of development of children born after in vitro maturation of oocytes. Hum Reprod 2006;21:1508-13.
71. Oktay K, Demirtas E, Son WY, Lostritto K, Chian RC, Tan SL. In vitro maturation of germinal vesicle oocytes recovered after premature luteinizing hormone surge: description of a novel approach to fertility preservation. Fertil Steril 2007 May 19; [Epub ahead of print]
72. Huang JYJ, Buckett WM, Gilbert L, Tan SL, Chian R. Retrieval of immature oocytes followed by in vitro maturation and vitrification: A case report on a new strategy of fertility preservation in women with borderline ovarian malignancy. Gynecol Oncol 2007;105:542-4.
73. Oktay K. Ovarian tissue cryopreservation and transplantation: preliminary findings and implications for cancer patients. Hum Reprod Update 2001;7:526-34.
74. Gosden RG, Baird DT, Wade JC, Webb R. Restoration of fertility o oophorectomized sheep by ovarian autografts stored at -196 degrees C. Hum Reprod 1994;9:597-603.
75. Sztein J, Sweet H, Farley J, Mobraaten L. Cryopreservation and orthotopic transplantation of mouse ovaries: new approach in gamete banking. Biol Reprod 1998;58:1071-4.
76. Liu J, Van der Elst J, Van den Broecke R, Dhont M. Live offspring by in vitro fertilization of oocytes from cryopreserved primordial Mouse follicles after sequential in vivo transplantation and in vitro maturation. Biol Reprod 2001;64:171-8.
77. Sonmezer M, Shamonki MI, Oktay K. Ovarian tissue cryopreservation: benefits and risks. Cell Tissue Res 2005;322:125-32.
78. Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001;286:1490-3.
79. Oktay K, Buyuk E, Veeck L, Zaninovic N, Xu K, Takeuchi T et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;363:837-40.
80. Imhof M, Bergmeister H, Lipovac M, Rudas M, Hofstetter G, Huber J. Orthotopic microvascular reanastomosis of whole cryopreserved ovine ovaries resulting in pregnancy and live birth. Fertil Steril 2006;85 Suppl 1:1208-15.
81. Imhof M, Hofstetter G, Bergmeister H, Rudas M, Kain R, Lipovac M. Cryopreservation of a whole ovary as a strategy for restoring ovarian function. J Assist Reprod Genet 2004;21:459-65.
82. Bedaiwy MA, Hussein MR, Biscotti C, Falcone T. Cryopreservation of intact human ovary with its vascular pedicle. Hum Reprod 2006;21:3258-69.
83. Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 2000;342:1919.
84. Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405-10.
85. Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005;353:318-21.
86. Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. Obstet Gynecol 1994;84:449-52.
87. Borst MJ, Ingold JA. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 1993;114:637-41.
88. Perrotin F, Marret H, Bouquin R, Fischer-Perrotin N, Lansac J, Body G. Incidence, diagnosis and prognosis of ovarian metastasis in breast cancer. Gynecol Obstet Fertil 2001;29:308-15.
89. rd ed. New York: Springer Verlag; 1987.p.742-68.
90. Oktay K, Sonmezer M. Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 2004;19:477-80.
91. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. J Am Med Assoc 2003;289:1421-4.
92. Oktay K, Sonmezer M, Oktem O. Ovarian cryopreservation versus ovarian suppression by GnRH analogues: primum non nocere: reply. Hum Reprod 2004;19:1681-3.
93. Blumenfeld Z. Ovarian cryopreservation versus ovarian suppression by GnRH analogues: primum non nocere. Hum Reprod 2004;19:1924-5.
94. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Heejung B. Absence of the conclusive evidence for the safety and efficacy of the gonadotropin releasing hormone analog treatment in protecting against chemotherapy-induced gonadal injury. Oncologist In press.
95. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987;19:159-62.
96. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7.
97. Pereyra-Pacheco B, Mendez-Ribaz JM, Milone G, Fernández I, Kvicala R, Mila T et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391-7.
98. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002;13 Suppl 1:138-47.
99. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig 2001;8 Suppl 1:60-4.
100. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 2002;22:93-105.
101. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11:1620-6.
102. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:401-5.
103. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-23.
104. Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006;17:74-8.
105. Meduri G, Touraine P, Beau I, Lahuna O, Desroches A, Vacher-Lavenu MC et al. Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle stimulating hormone receptor: clinical, histological, and molecular studies. J Clin Endocrinol Metab 2003;88:3491-8.
106. Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 1997;82:3748-51.
107. Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 2001;16:632-7.
108. Pydyn EF, Ataya KM. Effect of cyclophosphamide on mouse oocyte in vitro fertilization and cleavage: recovery. Reprod Toxicol 1991;5:73-8.
109. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ et al. Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy on Early Breast Cancer. Ann Oncol 2005;16: 1569-83.
110. Dawood MY, Ramos J, Khan-Dawood FS. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertil Steril 1995;63:1177-83.
111. Oktay K, Nugent D, Newton H, Salha O, Chatterjee P, Gosden RG. Isolation and characterization of primordial follicles from fresh and cryopreserved human ovarian tissue. Fertil Steril 1997;67:481-6.
112. Oktem O, Oktay K. The role of extracellular matrix and activin-A in in vitro growth and survival of murine preantral follicles. Reprod Sci. In press 2007.
113. Oktay K, Newton H, Mullan J, Gosden RG. Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum Reprod 1998;13:1133-8.
114. Gook DA, Edgar DH, Borg J, Archer J, Lutjen PJ, McBain JC. Oocyte maturation, follicle rupture and luteinization in human cryopreserved ovarian tissue following xenografting. Hum Reprod 2003;18:1772-81.
115. Morita Y, Tilly JL. Oocyte apoptosis: like sand through an hourglass. Dev Biol 1999;213:1-17.
116. Morita Y, Perez GI, Paris F Miranda SR, Ehleiter D, Haimovitz-Friedman A et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000;6:1109-14.
117. Paris F, Perez GI, Fuks Z, Haimovitz-Friedman A, Nguyen H, Bose M et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002;8:901-2.